Skip to Main content Skip to Navigation
Journal articles

Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease

Abstract : Simple Summary: Multiple myeloma is a cancer that remains incurable. Among the many therapies under evaluation, antibodies can be used as vehicles to target and deliver toxic radiation to the tumour cells. Our objective was therefore to investigate the potential of targeted alpha therapy, combining an anti-CD138 mAb with astatine-211, to destroy the residual cells responsible for relapse. We have shown in a mouse model that mimics human disease, that destroying multiple myeloma cells is feasible with low toxicity by injecting an anti-CD138 mAb coupled with astatine-211. This approach could eradicate residual cells after initial treatment and thus prevent recurrence. Abstract: Despite therapeutic progress in recent years with the introduction of targeted therapies (daratumumab, elotuzumab), multiple myeloma remains an incurable cancer. The question is therefore to investigate the potential of targeted alpha therapy, combining an anti-CD138 antibody with astatine-211, to destroy the residual cells that cause relapses. A preclinical syngeneic mouse model, consisting of IV injection of 1 million of 5T33 cells in a KaLwRij C57/BL6 mouse, was treated 10 days later with an anti-mCD138 antibody, called 9E7.4, radiolabeled with astatine-211. Four activities of the 211 At-9E7.4 radioimmunoconjugate were tested in two independent experiments: 370 kBq (n = 16), 555 kBq (n = 10), 740 kBq (n = 17) and 1100 kBq (n = 6). An isotype control was also tested at 555 kBq (n = 10). Biodistribution, survival rate, hematological parameters, enzymatic hepatic toxicity, histological examination and organ dosimetry were considered. The survival median of untreated mice was 45 days after engraftment. While the activity of 1100 kBq was highly toxic, the activity of 740 kBq offered the best efficacy with 65% of overall survival 150 days after the treatment with no evident sign of toxicity. This work demonstrates the pertinence of treating minimal residual disease of multiple myeloma with an anti-CD138 antibody coupled to astatine-211.
Document type :
Journal articles
Complete list of metadata

Cited literature [57 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-03006927
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, November 16, 2020 - 10:38:37 AM
Last modification on : Wednesday, November 18, 2020 - 3:05:48 AM
Long-term archiving on: : Wednesday, February 17, 2021 - 6:33:37 PM

File

Gouard2020Eq13.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Sébastien Gouard, Catherine Saï-Maurel, Séverine Marionneau-Lambot, Delphine Dansette, Clément Bailly, et al.. Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease. Cancers, MDPI, In press, 12 (9), pp.2721. ⟨10.3390/cancers12092721⟩. ⟨inserm-03006927⟩

Share

Metrics

Record views

114

Files downloads

162